Anti-CTLA4 Blockade Alone or Combined With Systemic GM-CSF for Prostate Cancer Immunotherapy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2015
At a glance
- Drugs Ipilimumab (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 02 Oct 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
- 24 Jun 2014 Planned initiation date changed from 1 Feb 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.